π¬Deep Research
CATX β Perspective Therapeutics Inc Β· catalysts, narrative & risks
Perspective Therapeutics, Inc. (NYSE American: CATX) β Research Snapshot
As of the Oct 16, 2026 close, CATX traded around $2.17 (down 7.3% that day), with a market capitalization of roughly $247.7Mβ$267.1M (sources differ) and a 52-week range of $1.96β$6.16 [8] [11] [14] [20] [26]. It carries a high beta (1.85), negative TTM EPS (-$1.33), ~$236.9M in cash, and no meaningful trailing revenue [8] [20] [24]. It is a clinical-stage radiopharmaceutical developer using its lead-212 (Β²ΒΉΒ²Pb) alpha-therapy platform [3] [24].
Key Recent Catalysts (JulyβOctober 2026)
AI-assisted research from the K3vl4r desk β not personalized investment advice. More research β